| Dr Ryan Biegler, MD | |
|
3600 Nw Samaritan Dr, Corvallis, OR 97330-3737 | |
| (541) 768-5111 | |
| Not Available |
| Full Name | Dr Ryan Biegler |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 20 Years |
| Location | 3600 Nw Samaritan Dr, Corvallis, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386866507 | NPI | - | NPPES |
| 274460 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | MD27344 (Oregon) | Secondary |
| 207R00000X | Internal Medicine | MD27344 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Good Samaritan Regional Medical Center | Corvallis, OR | Hospital |
| Samaritan Albany General Hospital | Albany, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Good Samaritan Hospital Corvallis | 1557270725 | 339 |
News Archive
Bladder cancer will kill upward of 170,000 people worldwide this year, but bladder cancer isn't fatal in the bladder. Instead, in order to be fatal the disease must metastasize to faraway sites. The question has been this: does localized, non-muscle invasive bladder cancer eventually become the more dangerous, muscle-invasive form of the disease, or are NMI and MI bladder cancers genetically distinct from the start?
University of Manchester scientists have led an international team to discover new treatments for a rare and potentially lethal childhood disease that is the clinical opposite of diabetes mellitus.
EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, announced today the execution of an amendment to its agreement with Opexa Therapeutics, Inc. for the development and commercialization of its investigational compound Tcelna (imilecleucel-T).
One of the frustrations for scientists working on HIV/AIDS treatments has been the human immunodeficiency virus' ability to evade the body's immune system. Now an Indiana University researcher has discovered a compound that could help put the immune system back in the hunt.
The challenge of treating patients with genetic disorders in which a single mutated gene is simply too large to be replaced using traditional gene therapy techniques may soon be a thing of the past. A Nationwide Children's Hospital study describes a new gene therapy approach capable of delivering full-length versions of large genes and improving skeletal muscle function. The strategy may hold new hope for treating dysferlinopathies and other muscular dystrophies.
› Verified 3 days ago
| Entity Name | Mid-valley Healthcare Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689625980 PECOS PAC ID: 2769391523 Enrollment ID: O20031111000297 |
News Archive
Bladder cancer will kill upward of 170,000 people worldwide this year, but bladder cancer isn't fatal in the bladder. Instead, in order to be fatal the disease must metastasize to faraway sites. The question has been this: does localized, non-muscle invasive bladder cancer eventually become the more dangerous, muscle-invasive form of the disease, or are NMI and MI bladder cancers genetically distinct from the start?
University of Manchester scientists have led an international team to discover new treatments for a rare and potentially lethal childhood disease that is the clinical opposite of diabetes mellitus.
EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, announced today the execution of an amendment to its agreement with Opexa Therapeutics, Inc. for the development and commercialization of its investigational compound Tcelna (imilecleucel-T).
One of the frustrations for scientists working on HIV/AIDS treatments has been the human immunodeficiency virus' ability to evade the body's immune system. Now an Indiana University researcher has discovered a compound that could help put the immune system back in the hunt.
The challenge of treating patients with genetic disorders in which a single mutated gene is simply too large to be replaced using traditional gene therapy techniques may soon be a thing of the past. A Nationwide Children's Hospital study describes a new gene therapy approach capable of delivering full-length versions of large genes and improving skeletal muscle function. The strategy may hold new hope for treating dysferlinopathies and other muscular dystrophies.
› Verified 3 days ago
| Entity Name | Good Samaritan Hospital Corvallis |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962453134 PECOS PAC ID: 1557270725 Enrollment ID: O20031125000163 |
News Archive
Bladder cancer will kill upward of 170,000 people worldwide this year, but bladder cancer isn't fatal in the bladder. Instead, in order to be fatal the disease must metastasize to faraway sites. The question has been this: does localized, non-muscle invasive bladder cancer eventually become the more dangerous, muscle-invasive form of the disease, or are NMI and MI bladder cancers genetically distinct from the start?
University of Manchester scientists have led an international team to discover new treatments for a rare and potentially lethal childhood disease that is the clinical opposite of diabetes mellitus.
EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, announced today the execution of an amendment to its agreement with Opexa Therapeutics, Inc. for the development and commercialization of its investigational compound Tcelna (imilecleucel-T).
One of the frustrations for scientists working on HIV/AIDS treatments has been the human immunodeficiency virus' ability to evade the body's immune system. Now an Indiana University researcher has discovered a compound that could help put the immune system back in the hunt.
The challenge of treating patients with genetic disorders in which a single mutated gene is simply too large to be replaced using traditional gene therapy techniques may soon be a thing of the past. A Nationwide Children's Hospital study describes a new gene therapy approach capable of delivering full-length versions of large genes and improving skeletal muscle function. The strategy may hold new hope for treating dysferlinopathies and other muscular dystrophies.
› Verified 3 days ago
| Entity Name | Samaritan North Lincoln Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306897491 PECOS PAC ID: 7911816301 Enrollment ID: O20040120000329 |
News Archive
Bladder cancer will kill upward of 170,000 people worldwide this year, but bladder cancer isn't fatal in the bladder. Instead, in order to be fatal the disease must metastasize to faraway sites. The question has been this: does localized, non-muscle invasive bladder cancer eventually become the more dangerous, muscle-invasive form of the disease, or are NMI and MI bladder cancers genetically distinct from the start?
University of Manchester scientists have led an international team to discover new treatments for a rare and potentially lethal childhood disease that is the clinical opposite of diabetes mellitus.
EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, announced today the execution of an amendment to its agreement with Opexa Therapeutics, Inc. for the development and commercialization of its investigational compound Tcelna (imilecleucel-T).
One of the frustrations for scientists working on HIV/AIDS treatments has been the human immunodeficiency virus' ability to evade the body's immune system. Now an Indiana University researcher has discovered a compound that could help put the immune system back in the hunt.
The challenge of treating patients with genetic disorders in which a single mutated gene is simply too large to be replaced using traditional gene therapy techniques may soon be a thing of the past. A Nationwide Children's Hospital study describes a new gene therapy approach capable of delivering full-length versions of large genes and improving skeletal muscle function. The strategy may hold new hope for treating dysferlinopathies and other muscular dystrophies.
› Verified 3 days ago
| Entity Name | Samaritan Pacific Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174888010 PECOS PAC ID: 2466353529 Enrollment ID: O20040204000304 |
News Archive
Bladder cancer will kill upward of 170,000 people worldwide this year, but bladder cancer isn't fatal in the bladder. Instead, in order to be fatal the disease must metastasize to faraway sites. The question has been this: does localized, non-muscle invasive bladder cancer eventually become the more dangerous, muscle-invasive form of the disease, or are NMI and MI bladder cancers genetically distinct from the start?
University of Manchester scientists have led an international team to discover new treatments for a rare and potentially lethal childhood disease that is the clinical opposite of diabetes mellitus.
EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, announced today the execution of an amendment to its agreement with Opexa Therapeutics, Inc. for the development and commercialization of its investigational compound Tcelna (imilecleucel-T).
One of the frustrations for scientists working on HIV/AIDS treatments has been the human immunodeficiency virus' ability to evade the body's immune system. Now an Indiana University researcher has discovered a compound that could help put the immune system back in the hunt.
The challenge of treating patients with genetic disorders in which a single mutated gene is simply too large to be replaced using traditional gene therapy techniques may soon be a thing of the past. A Nationwide Children's Hospital study describes a new gene therapy approach capable of delivering full-length versions of large genes and improving skeletal muscle function. The strategy may hold new hope for treating dysferlinopathies and other muscular dystrophies.
› Verified 3 days ago
| Entity Name | Albany General Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154372340 PECOS PAC ID: 9931097987 Enrollment ID: O20040310000310 |
News Archive
Bladder cancer will kill upward of 170,000 people worldwide this year, but bladder cancer isn't fatal in the bladder. Instead, in order to be fatal the disease must metastasize to faraway sites. The question has been this: does localized, non-muscle invasive bladder cancer eventually become the more dangerous, muscle-invasive form of the disease, or are NMI and MI bladder cancers genetically distinct from the start?
University of Manchester scientists have led an international team to discover new treatments for a rare and potentially lethal childhood disease that is the clinical opposite of diabetes mellitus.
EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, announced today the execution of an amendment to its agreement with Opexa Therapeutics, Inc. for the development and commercialization of its investigational compound Tcelna (imilecleucel-T).
One of the frustrations for scientists working on HIV/AIDS treatments has been the human immunodeficiency virus' ability to evade the body's immune system. Now an Indiana University researcher has discovered a compound that could help put the immune system back in the hunt.
The challenge of treating patients with genetic disorders in which a single mutated gene is simply too large to be replaced using traditional gene therapy techniques may soon be a thing of the past. A Nationwide Children's Hospital study describes a new gene therapy approach capable of delivering full-length versions of large genes and improving skeletal muscle function. The strategy may hold new hope for treating dysferlinopathies and other muscular dystrophies.
› Verified 3 days ago
| Entity Name | Samaritan North Lincoln Hospital |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1306897491 PECOS PAC ID: 7911816301 Enrollment ID: O20061104000117 |
News Archive
Bladder cancer will kill upward of 170,000 people worldwide this year, but bladder cancer isn't fatal in the bladder. Instead, in order to be fatal the disease must metastasize to faraway sites. The question has been this: does localized, non-muscle invasive bladder cancer eventually become the more dangerous, muscle-invasive form of the disease, or are NMI and MI bladder cancers genetically distinct from the start?
University of Manchester scientists have led an international team to discover new treatments for a rare and potentially lethal childhood disease that is the clinical opposite of diabetes mellitus.
EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, announced today the execution of an amendment to its agreement with Opexa Therapeutics, Inc. for the development and commercialization of its investigational compound Tcelna (imilecleucel-T).
One of the frustrations for scientists working on HIV/AIDS treatments has been the human immunodeficiency virus' ability to evade the body's immune system. Now an Indiana University researcher has discovered a compound that could help put the immune system back in the hunt.
The challenge of treating patients with genetic disorders in which a single mutated gene is simply too large to be replaced using traditional gene therapy techniques may soon be a thing of the past. A Nationwide Children's Hospital study describes a new gene therapy approach capable of delivering full-length versions of large genes and improving skeletal muscle function. The strategy may hold new hope for treating dysferlinopathies and other muscular dystrophies.
› Verified 3 days ago
| Entity Name | Mid-valley Healthcare Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1689625980 PECOS PAC ID: 2769391523 Enrollment ID: O20061104000140 |
News Archive
Bladder cancer will kill upward of 170,000 people worldwide this year, but bladder cancer isn't fatal in the bladder. Instead, in order to be fatal the disease must metastasize to faraway sites. The question has been this: does localized, non-muscle invasive bladder cancer eventually become the more dangerous, muscle-invasive form of the disease, or are NMI and MI bladder cancers genetically distinct from the start?
University of Manchester scientists have led an international team to discover new treatments for a rare and potentially lethal childhood disease that is the clinical opposite of diabetes mellitus.
EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, announced today the execution of an amendment to its agreement with Opexa Therapeutics, Inc. for the development and commercialization of its investigational compound Tcelna (imilecleucel-T).
One of the frustrations for scientists working on HIV/AIDS treatments has been the human immunodeficiency virus' ability to evade the body's immune system. Now an Indiana University researcher has discovered a compound that could help put the immune system back in the hunt.
The challenge of treating patients with genetic disorders in which a single mutated gene is simply too large to be replaced using traditional gene therapy techniques may soon be a thing of the past. A Nationwide Children's Hospital study describes a new gene therapy approach capable of delivering full-length versions of large genes and improving skeletal muscle function. The strategy may hold new hope for treating dysferlinopathies and other muscular dystrophies.
› Verified 3 days ago
| Entity Name | Samaritan Pacific Health Services Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1801847066 PECOS PAC ID: 2466353529 Enrollment ID: O20061104000163 |
News Archive
Bladder cancer will kill upward of 170,000 people worldwide this year, but bladder cancer isn't fatal in the bladder. Instead, in order to be fatal the disease must metastasize to faraway sites. The question has been this: does localized, non-muscle invasive bladder cancer eventually become the more dangerous, muscle-invasive form of the disease, or are NMI and MI bladder cancers genetically distinct from the start?
University of Manchester scientists have led an international team to discover new treatments for a rare and potentially lethal childhood disease that is the clinical opposite of diabetes mellitus.
EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, announced today the execution of an amendment to its agreement with Opexa Therapeutics, Inc. for the development and commercialization of its investigational compound Tcelna (imilecleucel-T).
One of the frustrations for scientists working on HIV/AIDS treatments has been the human immunodeficiency virus' ability to evade the body's immune system. Now an Indiana University researcher has discovered a compound that could help put the immune system back in the hunt.
The challenge of treating patients with genetic disorders in which a single mutated gene is simply too large to be replaced using traditional gene therapy techniques may soon be a thing of the past. A Nationwide Children's Hospital study describes a new gene therapy approach capable of delivering full-length versions of large genes and improving skeletal muscle function. The strategy may hold new hope for treating dysferlinopathies and other muscular dystrophies.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ryan Biegler, MD Po Box 1189, Corvallis, OR 97339-1189 Ph: () - | Dr Ryan Biegler, MD 3600 Nw Samaritan Dr, Corvallis, OR 97330-3737 Ph: (541) 768-5111 |
News Archive
Bladder cancer will kill upward of 170,000 people worldwide this year, but bladder cancer isn't fatal in the bladder. Instead, in order to be fatal the disease must metastasize to faraway sites. The question has been this: does localized, non-muscle invasive bladder cancer eventually become the more dangerous, muscle-invasive form of the disease, or are NMI and MI bladder cancers genetically distinct from the start?
University of Manchester scientists have led an international team to discover new treatments for a rare and potentially lethal childhood disease that is the clinical opposite of diabetes mellitus.
EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, announced today the execution of an amendment to its agreement with Opexa Therapeutics, Inc. for the development and commercialization of its investigational compound Tcelna (imilecleucel-T).
One of the frustrations for scientists working on HIV/AIDS treatments has been the human immunodeficiency virus' ability to evade the body's immune system. Now an Indiana University researcher has discovered a compound that could help put the immune system back in the hunt.
The challenge of treating patients with genetic disorders in which a single mutated gene is simply too large to be replaced using traditional gene therapy techniques may soon be a thing of the past. A Nationwide Children's Hospital study describes a new gene therapy approach capable of delivering full-length versions of large genes and improving skeletal muscle function. The strategy may hold new hope for treating dysferlinopathies and other muscular dystrophies.
› Verified 3 days ago
Tomer Pelleg, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3600 Nw Samaritan Dr Ste 227, Corvallis, OR 97330 Phone: 541-768-1261 | |
Dr. Parinav Kanwar, Internal Medicine Medicare: Medicare Enrolled Practice Location: 3600 Nw Samaritan Dr, Corvallis, OR 97330 Phone: 541-768-4906 | |
Dr. Stanley J. Nudelman, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3521 Nw Samaritan Dr, Suite 201, Corvallis, OR 97330 Phone: 541-768-5140 | |
Dr. Randall V. Bream, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 3600 Nw Samaritan Dr, Suite E350, Corvallis, OR 97330 Phone: 541-768-5205 Fax: 541-768-5206 | |
Jonathan David Jones, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3620 Nw Samaritan Dr Ste 202, Corvallis, OR 97330 Phone: 541-768-5800 | |
Gemechu Abraham Geleto, Internal Medicine Medicare: Medicare Enrolled Practice Location: 3600 Nw Samaritan Dr, Corvallis, OR 97330 Phone: 541-768-4906 | |
Roland Solensky, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3680 Nw Samaritan Dr, Corvallis, OR 97330 Phone: 541-754-1150 |